Donate
A mouse genetics study shows that disrupting lysine alpha-ketoglutarate reductase (LKR) upstream of ALDH7A1 can eliminate toxic intermediates and reverse seizures and cognitive deficits in an ALDH7A1-deficient model.
Even when pyridoxine controls seizures, many people with PDE-ALDH7A1 still experience developmental or cognitive challenges. That has fueled a big research question: can we reduce the toxic metabolite burden itself, not just “treat the seizures”?
This study tests substrate reduction therapy by genetically perturbing LKR, an upstream enzymatic activity within the lysine catabolism pathway (associated with the bifunctional AASS enzyme). In ALDH7A1-deficient mice, a homozygous LKR mutation prevented accumulation of the toxic intermediates alpha-AASA and P6C, ended the epileptic state, and restored aspects of brain development and cognition.
The deeper scientific significance is that this is clean causal evidence for pathway-flux control: if you lower the pipeline’s input upstream, you can remove the downstream toxic bottleneck even when the “broken” ALDH7A1 step remains broken. Because complete LKR/AASS deficiency (hyperlysinemia type I) is often described as mild or clinically benign, LKR inhibition is framed as a plausible therapeutic window, motivating efforts to find drug-like or RNA-based ways to partially inhibit this step in humans.
Why this matters
It strengthens the case for upstream therapies (like LKR/AASS inhibition) as a strategy to address long-term neurological outcomes, not just immediate seizure control.
Limitations
This is a genetic mouse study, not a human trial. Translating “gene knockout” into a safe, targeted, adjustable therapy for children will require extensive work.
Sources
- “Targeting Lysine alpha-Ketoglutarate Reductase to Treat Pyridoxine-Dependent Epilepsy.” Journal of Neuroscience (2025). DOI: 10.1523/JNEUROSCI.0370-25.2025 (PubMed: 40335153; Free full text: PMC12139589)
Safety note: This summary is educational and not medical advice.
